LifeSteps Financial Inc. Has $1.17 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Mar 28th, 2023

LifeSteps Financial Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 27.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,602 shares of the company’s stock after purchasing an additional 1,415 shares during the period. Johnson & Johnson accounts for 1.2% of LifeSteps Financial Inc.’s holdings, making the stock its 22nd biggest holding. LifeSteps Financial Inc.’s holdings in Johnson & Johnson were worth $1,166,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Family Asset Management LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $681,000. Atlas Private Wealth Management lifted its position in shares of Johnson & Johnson by 6.5% in the 4th quarter. Atlas Private Wealth Management now owns 20,200 shares of the company’s stock worth $3,568,000 after purchasing an additional 1,234 shares during the period. Retirement Financial Solutions LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at $40,000. Bennett Selby Investments LP increased its position in shares of Johnson & Johnson by 0.5% during the fourth quarter. Bennett Selby Investments LP now owns 17,045 shares of the company’s stock worth $3,011,000 after buying an additional 85 shares during the period. Finally, Obsidian Personal Planning Solutions LLC lifted its holdings in Johnson & Johnson by 21.1% in the fourth quarter. Obsidian Personal Planning Solutions LLC now owns 2,872 shares of the company’s stock valued at $507,000 after buying an additional 501 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Citigroup increased their price target on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Morgan Stanley increased their price target on Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 25th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a “strong-buy” rating on the stock. Finally, SVB Leerink reduced their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $174.73.

Johnson & Johnson Trading Up 0.4 %

NYSE:JNJ opened at $153.30 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. Johnson & Johnson has a one year low of $150.11 and a one year high of $186.69. The company has a market cap of $399.24 billion, a PE ratio of 22.74, a PEG ratio of 2.63 and a beta of 0.54. The firm has a 50-day moving average of $159.35 and a 200-day moving average of $167.49.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.13 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.